Skip to main content
. 2021 Jan 1;11(5):2098–2107. doi: 10.7150/thno.48027

Figure 4.

Figure 4

Prognostic performance of clinical model and fusion model. (A, B and C) were the KM curves which indicated progression-free survival (PFS) of patients relative to clinical model in entire immunotherapy cohort, pembrolizumab-monotherapy group and pembrolizumab combined with chemotherapy group, respectively. (D, E and F) were the KM curves which indicated PFS of patients relative to combination of PD-L1 expression signature (PD-L1ES) and clinical model in entire immunotherapy cohort, pembrolizumab-monotherapy group and pembrolizumab combined with chemotherapy group, respectively.